Basic Information
Insamo is a biotechnology company dedicated to developing orally available cyclic peptides with antibody-like binding affinity and membrane permeability. The platform combines ML-driven molecular design, ultra-high-throughput molecular biology, and parallel synthetic chemistry to identify preclinical candidates with favorable pharmacological properties. Their goal includes replacing injectable or infusion-based biologics with easy-to-administer oral cyclic peptide formulations, thereby enhancing patient care and accelerating drug discovery for currently challenging drug targets. Their solution enables the generation of candidate therapeutics from scratch without prior knowledge of the structure, dynamics, or "druggable" sites of disease targets, requiring only a small amount of target material.